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Introduction
Acute renal infarction (ARI), which is a rare cause of flank pain, 
results from interruption in the blood supply of renal tissue. The sever-
ity of its clinic depends on the width of the affected part of the kidney. 
It is often impossible to find the underlying cause (1, 2). Thromboembolic 
states related to cardiac diseases, such as atrial fibrillation, rheumatic 
mitral stenosis, endocarditis, and left ventricular wall aneurysms, are 
the major causes, whereas occlusion of the renal artery following 
endovascular aortic or renal intervention, renovascular diseases, 
malignant hypertension, paradoxical cardiac emboli associated with 
atrial septal defects, polyarteritis nodosa, and cocaine have also been 
reported as rare causes in the etiology (3-5). In the literature, the inci-
dence of ARI lies within a range of 0.007%-1.4% (1-5).
Herein, we present a patient with ARI and its treatment with a novel 
oral anticoagulant, dabigatran.
Case Report
A 55-year-old male patient was admitted to our emergency depart-
ment with right flank tenderness preceding 4-6 hours. 
He had no dysuria, hematuria, fever, nausea, or vomiting. Except for the 
right flank tenderness and 3/6 systolic murmur at the cardiac apex, his 
physical examination and hemodynamic parameters were normal. His 
medical history was remarkable for non-ischemic dilated cardiomyopa-
thy, which was diagnosed by coronary angiography (CAG) and cardiac 
catheterization in another clinic 2 days ago, and the drugs in use were 
carvedilol, ramipril, furosemide, and acetylsalicylic acid. The abdominal 
x-ray, urinary ultrasonography (US), and laboratory analysis were all 
normal. Only mild microscopic hematuria was detected. The patient 
was clinically diagnosed with renal colic, treated with analgesics, and 
then discharged home for further ambulatory urologic investigation. A 
few hours later, the patient returned to the emergency department with 
severe right flank pain. On contrast-enhanced computed tomography 
(CECT), performed for persistent flank pain, to rule out nephrolithiasis 
and CAG complications, such as retroperitoneal hematoma, a 
hypodense, non-enhancing, wedge-shaped area in the right kidney, 
which was compatible with renal infarction, was seen (Fig. 1A). Globally 
systolic dysfunction (ejection fraction: 35%), mild-moderate mitral 
insufficiency, dilated left chamber without thrombi or vegetation, and 
multiple self-terminating atrial fibrillation (AF) episodes compatible with 
paroxysmal AF were detected on transthoracic echocardiography and 
24-hour Holter monitoring, respectively. CHA2DS2-VASc and HAS-BLED 
scores were calculated as 3 and 2, respectively. Dabigatran (150 mg, 
b.i.d.), analgesics, and hydration were initiated. In 5 days, he recovered 
and was discharged home on dabigatran. On the control CECT scan per-
formed 1 month later, reperfusion and contrast enhancement were seen 
at the previously hypodense renal infarct area (Fig. 1B).
Discussion
The clinical diagnosis of ARI is frequently missed or delayed 
because of its nonspecific presentation, which can mimic more com-
mon conditions, such as nephrolithiasis, pyelonephritis, and appendici-
tis. X-ray and US, the primary imaging modalities for flank pain, have low 
sensitivity; so, CT is mostly performed for the differential diagnosis in 
patients with persistent severe flank pain. Magnetic resonance imaging 
with gadolinium and radioisotope scans are alternatives to CT in the 
Figure 1. A, B. Contrast-enhanced abdominal computed tomography images at the same level. (A) The hypodense, wedge-shaped infarct area in 
the right kidney (arrow). (B) One month later, reperfusion and contrast enhancement are seen at the previously hypodense infarct area (arrow). 
A slight decrease in cortical thickness is detected
A B
diagnosis of ARI. Inflammatory symptoms and parameters can be help-
ful to rule out infection (lobar nephronia/pyelonephritis) (6, 7). 
There are no clinical research data or therapeutic guidelines for 
renal artery embolism; however, hydration, systemic anticoagulation, 
percutaneous endovascular therapy, local thrombolysis, and surgical 
embolectomia are recommended treatment options in limited reports. 
Conservative therapy is favorable in unilateral ARI (8). Common concepts 
for anticoagulation therapy in ARI are intravenous heparin, followed by 
oral warfarin. Unlike other cases in the literature, we preferred oral 
dabigatran (150 mg, b.i.d.) for anticoagulation. Although there is no spe-
cific suggestion about the usage of dabigatran in ARI, the American 
College of Cardiology and American Heart Association have recom-
mended that dabigatran is useful as an alternative to warfarin for the 
prevention of stroke and systemic embolism in patients with paroxysmal 
to permanent AF and risk factors for stroke or systemic embolization 
who do not have a prosthetic heart valve or hemodynamically significant 
valve disease, severe renal failure (creatine clearance <15 mL/min), or 
advanced liver disease (impaired baseline clotting function) (9, 10).
In patients with a high risk of systemic thromboembolism and pre-
senting with flank tenderness, ARI should be kept in mind to prevent a 
delayed or missed diagnosis. Clinicians should be aware of the clinical 
importance of paroxysmal AF, which has similar risks for stroke and 
systemic embolism as permanent AF. Also, 24-hour Holter monitoring 
can be useful to detect underlying causes of ARI. In our case, we har-
vested an excellent clinical outcome with the proper diagnostic and 
treatment methods.
Conclusion
Dabigatran can be preferred as an oral anticoagulant in the conser-
vative therapy of systemic embolisms, like ARI. Clinical usage of dabiga-
tran in such rare cases will help clinicians in their daily practice.
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